There are many pharmacologic therapies that are being used or considered for treatment of
coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Background Patients with underlying medical conditions are at increased risk for severe
coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over …

Recent studies have reported the protective efficacy of both natural and vaccine-induced,,,,–
immunity against challenge with severe acute respiratory syndrome coronavirus 2 (SARS …

Severe covid-19 pneumonia has posed critical challenges for the research and medical
communities. Older age, male sex, and comorbidities increase the risk for severe disease …

Objective To investigate the effectiveness of using convalescent plasma to treat moderate
coronavirus disease 2019 (covid-19) in adults in India. Design Open label, parallel arm …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

At the stroke of the New Year 2020, COVID-19, a zoonotic disease that would turn into a
global pandemic, was identified in the Chinese city of Wuhan. Although unique in its …

Background Recent data suggest that complications and death from coronavirus disease
2019 (Covid-19) may be related to high viral loads. Methods In this ongoing, double-blind …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and …